CRF Design for Oncology Trials
Explore key considerations in Case Report Form (CRF) design for oncology clinical trials, highlighting the unique challenges in this therapeutic area.
Read more
![Real World Evidence in Drug Development [Podcast]](https://www.quanticate.com/hs-fs/hubfs/Real%20World%20Evidence%20Podcast-1.jpg?width=800&name=Real%20World%20Evidence%20Podcast-1.jpg)
Real World Evidence in Drug Development [Podcast]
Our statisticians discuss Real World Evidence and its importance on drug development, and how it can be used during COVID-19.
Read more
Real-Time Oncology Review (RTOR): First Drug Approval
RTOR can reduce the approval time for Oncology Clinical Trials without affecting the safety and effectiveness of the treatment.
Read more
Clinical Trial Outsourcing Trends and Research in 2020
Read the latest trends and predictions on clinical outsourcing and research due to new regulations and pressure to reduce the costs of drug development
Read more
The What, Why and How of Adaptive Clinical Trials
Quanticate explores the rise, the issues, and challenges of Adaptive Clinical Trials and the ways to adapt your study, with examples of oncology study design.
Read more
The Expansion Phase of Phase I Oncology Trials
Quanticate analyze whether having a Dose Expansion Phase in Phase I Oncology Trials is beneficial and provides information about Efficacy, Safety, Toxicity and Pharmacokinetics prior to jumping into a Phase II Study
Read more
Is Lack of Data the Biggest Challenge for Early Phase Pharmacovigilance?
A survey result on the challenges of pharmacovigilance in early phase clinical trials and solutions to a lack of data, complicated patients and protocol design
Read more
Efficacy Endpoints in Oncology and RECIST Criteria
Quanticate provides an overview of efficacy endpoints in oncology studies and the RECIST (Response Evaluation Criteria In Solid Tumours) method.
Read more
FOLLOW QUANTICATE ON:
© 2024 Quanticate